Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06867718 · ClinicalTrials.gov registry record · Phase 2
Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions
A Phase 2 study of Obesity or Overweight, sponsored by Regor Pharmaceuticals.
- Active
- Registry status
- Phase 2
- Development phase
- 236
- Enrollment target
- 20
- Study locations
NCT06867718: Active Phase 2 study of Obesity or Overweight, sponsored by Regor Pharmaceuticals.
NCT06867718 is a Phase 2 study of Obesity or Overweight that is active but no longer recruiting, run by Regor Pharmaceuticals. The registered enrollment target is 236 participants, below the 826-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06867718, a Phase 2 study of Obesity or Overweight, is active but no longer recruiting, sponsored by Regor Pharmaceuticals.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 236 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) with at least one weight-related comorbidity. RGT001-075 or matching placebo will be administered once daily.
Primary Outcome
Least Squares (LS) mean using mixed model repeated measures (MMRM)
Conditions Studied
Interventions
- DRUG Placebo Comparator
- DRUG RGT001-075
Study Locations (20)
Florida
- Angels Clinical Research - Doral
- Optimal Research - Melbourne
- Angels Clinical Research - Miami
- Palm Springs Community Health Center - Miami Lakes
- Synexus Clinical Research - The Villages
Georgia
- Javara-Privia Medical Group, Georgia LLC - Savannah
- Javara-Privia Medical Group, Georgia, LLC - Thomasville
Indiana
- Synexus Clinical Research - Evansville
- Velocity Clinical Research - Valparaiso
Minnesota
- Mankato Clinic-East Main Street-Javara - Mankato
- Synexus Clinical Research - Richfield
Alabama
- Alliance for Multispecialty Research, LLC - Mobile
Arizona
- Synexus Clinical Research - Phoenix
California
- Velocity Clinical Research - Huntington Park
Kentucky
- Alliance for Multispecialty Research, LLC - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 236 participants |
| Start Date | 2025-01-24 |
| Est. Completion | 2025-12-12 |
| Phase | Phase 2 |
What the registry record for NCT06867718 still lists
NCT06867718 is an interventional study that assigns participants to a tested intervention. The registered 236 participants enrollment target is mid-sized for trials with a published cap, below the 826-participant average among 6 other Obesity or Overweight trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Obesity or Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo Comparator is the first listed.
NCT06867718 names 20 study sites across 13 states, led by Florida, Georgia, Indiana.
Frequently Asked Questions
What is clinical trial NCT06867718 about?
NCT06867718 is a clinical study titled "Study of Once-Daily Oral RGT001-075 Compared With Placebo in Adults With Obesity or Are Overweight With Weight-Related Health Conditions". This is a phase 2, 36-week randomized, double-blind, placebo-controlled, parallel arm study that will evaluate the safety, tolerability, weight loss efficacy, pharmacodynamic effects, and pharmacokinetics of RGT001-075 in adults who are obese (BMI ≥30 kg/m²) or who are overweight (BMI ≥27 kg/m²) wit...
What is the current status of trial NCT06867718?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 236 participants. The study started on 2025-01-24. Estimated completion is 2025-12-12.
What conditions does trial NCT06867718 study?
This clinical trial studies the following conditions: Obesity or Overweight.
What interventions are being tested in trial NCT06867718?
The interventions under investigation include: Placebo Comparator (DRUG), RGT001-075 (DRUG).
Who is sponsoring clinical trial NCT06867718?
This trial is sponsored by Regor Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06867718 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity or Overweight
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Weight Loss Study Evaluating Subcutaneous Treatment With AZD9550 and AZD6234 in Combination Against Placebo or Each of the Drugs Alone
ACTIVE NOT RECRUITING · Phase 2
-
A Study Evaluating the Effect of Daily Oral RO7795081 in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity
ACTIVE NOT RECRUITING · Phase 2
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight Without Type 2 Diabetes
RECRUITING · Phase 3
-
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04995341 · 236 participants · NA
Retinal Microanatomy in Retinopathy of Prematurity (BabySTEPS2)
- NCT05822362 · 236 participants · Phase 2
CBD for Individuals at Risk for Alzheimer's Disease
- NCT06200103 · 236 participants · Phase 2
Schedule De-Escalation of 177Lu-PSMA-617 for the Treatment of Metastatic Castrate Resistant Prostate Cancer
- NCT06494072 · 236 participants · Phase 4
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI